Do we still need to do dual tracer localisation for sentinel node biopsy in patients with early breast cancer?

Abstract

Introduction: During COVID-19 pandemic the breast cancer services and practice changed significantly to minimise the exposure of patient or staff to COVID-19. The use of a single tracer (isotope) for localisation of sentinel node was suggested rather than gold standard dual tracer localisation by Association of Breast Surgery, UK. March 2020. This was done to avoid the small risk of anaphylaxis associated with blue dye, requiring ventilator support and thus straining the already overwhelmed ITUs.